Statistician at the University of Sheffield Clinical Trials Research Unit. Not that Mike Bradburn.
May 20, 2020 • 21 tweets • 7 min read
On international #clinicaltrialsday, it's worth* trial advocates (of which I'm one) taking a step back and acknowledging some of the limitations of the RCT.
* I think it's worth it and I've got a pre-print to publicise.
Here goes...(1/20)
Our paper asked: do RCT participants match their intended target population, and does it matter if they don't?
Short answers - probably not, and MAYBE not. There's many arguments and counter-arguments on this. I won't get them all in. (2/20)